Research ArticleOriginal Article
Open Access

Evaluation of clinical and laboratory characteristics and factors affecting mortality in 500 hospitalized COVID-19 patients

A retrospective study

Petek Ş. Konya, Neşe Demirtürk, Derya Korkmaz, Havva Tünay and Elif Betül Koşar
Saudi Medical Journal November 2022, 43 (11) 1254-1259; DOI: https://doi.org/10.15537/smj.2022.43.11.20220641

References

  1. 1.↵
    1. Aggarwal S,
    2. Garcia-Telles N,
    3. Aggarwal G,
    4. Lavie C,
    5. Lippi G,
    6. Henry BM.
    Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis (Berl) 2020; 7: 91–96.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cömert SŞ,
    2. Kıral N.
    Radiological findings of COVID-19 pneumonia. South Clin Ist Euras 2020; 31: 16–22.
    OpenUrl
  3. 3.↵
    Turkish Republic Ministry of Health COVID-19 Scientific Research Advisory Comitee. Adult Patient Treatment Guideline. 2021. [Updated 2020 May 30; cited 2020 Nov 4]. Availble from: https://hsgm.saglik.gov.tr/depo/covid19/Ingilizce/Rehber/COVID-19_Rehberi__Genel_bilgiler_epidemiyoloji_ve_tani_8.06.2020_eng.pdf
  4. 4.↵
    1. Kopel J,
    2. Perisetti A,
    3. Roghani A,
    4. Aziz M,
    5. Gajendran M,
    6. Goyal H.
    Racial and gender-based differences in COVID-19. Front Public Health 2020; 8: 418.
    OpenUrl
  5. 5.↵
    1. Wang D,
    2. Hu B,
    3. Hu C,
    4. Zhu F,
    5. Liu X,
    6. Zhang J, et al.
    Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Stasi C,
    2. Fallani S,
    3. Voller F,
    4. Silvestri C.
    Treatment for COVID-19: an overview. Eur J Pharmacol 2020; 889: 173644.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Fu L,
    2. Wang B,
    3. Yuan T,
    4. Chen X,
    5. Ao Y,
    6. Fitzpatrick T, et al.
    Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020; 80: 656–665.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Tian J,
    2. Yuan X,
    3. Xiao J,
    4. Zhong Q,
    5. Yang C,
    6. Liu B, et al.
    Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893–903.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Yang J,
    2. Zheng Y,
    3. Gou X,
    4. Pu K,
    5. Chen Z,
    6. Guo Q, et al.
    Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–95.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Dessie ZG,
    2. Zewotir T.
    Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021; 21: 855.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pourbagheri-Sigaroodi A,
    2. Bashash D,
    3. Fateh F,
    4. Abolghasemi H.
    Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta 2020; 510: 475–482.
    OpenUrl
  12. 12.↵
    1. Li Y,
    2. Hu Y,
    3. Yu J,
    4. Ma T.
    Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest 2020; 100: 794–800.
    OpenUrlPubMed
  13. 13.↵
    1. Kaya F,
    2. Konya PŞ,
    3. Demirel E,
    4. Demirtürk N,
    5. Orhan S,
    6. Ufuk F.
    Visual and quantitative assessment of COVID-19 pneumonia on chest CT: the relationship with disease severity and clinical findings. Curr Med imaging 2021; 17: 1142–1150.
    OpenUrl
  14. 14.↵
    1. Ben-Zvi I,
    2. Kivity S,
    3. Langevitz P,
    4. Shoenfeld Y.
    Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Fan J,
    2. Zhang X,
    3. Liu J,
    4. Yang Y,
    5. Zheng N,
    6. Liu Q, et al.
    Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating patients with coronavirus disease 2019. Clin Infect Dis 2020; 71: 3232–3236.
    OpenUrl
  16. 16.↵
    1. Furuta Y,
    2. Gowen BB,
    3. Takahashi K,
    4. Shiraki K,
    5. Smee DF,
    6. Barnard DL. Favipiravir
    (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100: 446–454.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Doi Y,
    2. Hibino M,
    3. Hase R,
    4. Yamamoto M,
    5. Kasamatsu Y,
    6. Hirose M, et al.
    A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020; 64: e01897–e01820.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Chen C,
    2. Zhang Y,
    3. Huang J,
    4. Yin P,
    5. Cheng Z,
    6. Wu J, et al.
    Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-Label, randomized controlled clinical trial. Front Pharmacol 2021; 12: 683296.
    OpenUrl
  19. 19.↵
    1. Stower H.
    Lopinavir-ritonavir in severe COVID-19. Nat Med 2020; 26: 465.
    OpenUrlCrossRef
  20. 20.↵
    1. Cao B,
    2. Wang Y,
    3. Wen D,
    4. Liu W,
    5. Wang J,
    6. Fan G, et al.
    A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382: 1787–1799.
    OpenUrlCrossRefPubMed
  21. 21.
    1. Qomara WF,
    2. Primanissa DN,
    3. Amalia SH,
    4. Purwadi FV,
    5. Zakiyah N.
    Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review. Int J Gen Med 2021; 14: 8557–8571.
    OpenUrl
  22. 22.↵
    1. Hassanipour S,
    2. Arab-Zozani M,
    3. Amani B,
    4. Heidarzad F,
    5. Fathalipour M,
    6. Martinez-de-Hoyo R.
    The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep 2021; 11: 11022.
    OpenUrl
  23. 23.↵
    1. Million M,
    2. Roussel Y,
    3. Gautret P,
    4. Raoult D.
    Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. Int J Antimicrob Agents 2021; 57: 106240.
    OpenUrl
  24. 24.↵
    1. Bhimraj A,
    2. Morgan RL,
    3. Shumaker AH,
    4. Lavergne V,
    5. Cheng VC,
    6. Edwards KM, et al.
    IDSA guidelines on the treatment and management of patients with COVID-19. [Updated 2022 Oct 10; cited 2020 Nov 4]. Available from: https://www.idsociety.org/COVID19guidelines
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords